Actively Recruiting
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
Led by Corewell Health East · Updated on 2025-12-11
166
Participants Needed
1
Research Sites
366 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this clinical trial is to compare the Emsella Chair therapy to Sham and to determine whether electromagnetic technology is effective in the treatment of overactive bladder (OAB). Currently there are no other studies utilizing the Emsella Chair for the treatment of OAB. Eligible subjects will receive 2 treatments per week for a total of 4 weeks.
CONDITIONS
Official Title
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to read, understand, and provide written informed consent and likely to comply with study procedures
- Men and women aged 18 years or older
- Self-reported bladder symptoms present for 3 months or more
- Self-reported failure of conservative care including behavioral changes or oral medications
- On a stable dose of antimuscarinics or beta-3 agonists for at least 4 weeks and willing to continue, or discontinued these medications for at least 2 weeks
- Able to walk and use a toilet independently without difficulty
- Agree not to start any new treatment for overactive bladder during the study treatment and follow-up
- For females of child-bearing age, agree to use approved birth control methods
You will not qualify if you...
- Botox use in bladder or pelvic floor muscles within the past year
- Weighing more than 330 pounds
- Pulmonary insufficiency causing breathing difficulty or fatigue
- Conditions causing loss of normal skin sensation in pelvis, buttocks, or thighs
- Major metal implants such as plates, screws, joint replacements, pacemakers, drug pumps, neurostimulators, electronic implants, copper IUDs, defibrillators, or pelvic metal implants
- Having a piercing between waist and knees that cannot be removed before treatment
- Active urethral diverticula
- Known vesicoureteral reflux
- Healing from surgery that would be disrupted by muscle contractions
- Current treatment for malignant tumors interfering with participation (skin cancers allowed)
- Previous use of BTL EMSELLA device
- Urinary incontinence caused by neurological diseases like multiple sclerosis or spinal cord injury
- Current urinary tract infection
- Use of neuromodulation therapy for bladder symptoms within 3 months
- Participation in another investigational study or use of investigational drugs within 30 days
- Any physical condition that may increase risk or affect study results
- For females, pregnancy or planning pregnancy during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Corewell Health William Beaumont University Hospital
Royal Oak, Michigan, United States, 48073
Actively Recruiting
Research Team
D
Danielle Tenney
CONTACT
J
Jennifer Giordano, BSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here